Furthermore, evidence suggests that the RAS pathway is hyper-activated in childhood AML patients with MLL-AF6 positive, and that PTPN11, as an important regulator of the RAS pathway, may contribute to this activation by causing SHP2 to remain active in the RAS pathway [45]. This evidence concerns the gene AFDN and acute myeloid leukemia.